-
MHM Automation - MHM
Could have sworn there was an MGL thread somewhere out there, but all the search would give me was the rather ancient BWY thead:
http://www.sharetrader.co.nz/showthr...Industries-Ltd
New management team in 2011 seem to be pulling things back on track. Combined with strong dairy industry demand (new production lines), potential residential building demand increase, growth from acquisitions (Titan Slicers) and launch of new products (e.g. today's announcement - previously foreshadowed - of North American licence agreement for the S-Clave technology). All starts to look like a baby version of SCT.
Okay, so 21 cps ($58m market cap) is probably more than a little overpriced... compare with SCT at $89m market cap and generating a $5m+ NPAT, whereas MGL managed just $0.8m. However, licensing revenues have the potential to drop through to bottom line rather nicely, so could provide a bit of a boost - especially should S-clave consumables start to kick in around 3-4 years away.
Should be a good first half due to strong order book and initial licence fee, so could be worth a short term trade for now, but otherwise just a heads up as one to keep a lazy eye on. AGM tomorrow may give further guidance.
Last edited by Lizard; 29-10-2021 at 06:43 PM.
Reason: Change Name and Ticker
-
The stock definitely has potential. From the annoucement...
"the deal should result in Mercer receiving an average royalty of at least 5%"
and
"Mercer estimates the North American sterilization market, including consumables, to be US$1.8 billion per annum"
-
Did anybody go to the AGM? Would have expected the AGM Presentation to be released by now. This would ensure all participants were equally informed.
Pity. Another cross for the company.
-
Originally Posted by noodles
Did anybody go to the AGM? Would have expected the AGM Presentation to be released by now. This would ensure all participants were equally informed.
Pity. Another cross for the company.
They must have heard me curse. The presentation is released.
Only interesting thing to note was that they were looking at funding options for the commercialization of s-clave. (capital raising perhaps?)
-
Yes, unclear whether the presentation triggered the sell, but a possible. $3m headroom on the banking facility, but then they say looking at funding options to commercialise S-clave ($2m). So suggestion there is both a cap raise AND that they may be soaking up working capital in the rest of the business.
Good and bad. Still think it is watchlist material - and would be good for it to get back to 10-14cps...
-
Originally Posted by Lizard
Yes, unclear whether the presentation triggered the sell, but a possible. $3m headroom on the banking facility, but then they say looking at funding options to commercialise S-clave ($2m). So suggestion there is both a cap raise AND that they may be soaking up working capital in the rest of the business.
Good and bad. Still think it is watchlist material - and would be good for it to get back to 10-14cps...
One of the more interesting ones IMHO Liz..
But there are so many :-)
-
Originally Posted by noodles
The stock definitely has potential. From the annoucement...
"the deal should result in Mercer receiving an average royalty of at least 5%"
and
"Mercer estimates the North American sterilization market, including consumables, to be US$1.8 billion per annum"
To much enthusiasm noodles.. Down boy.. Down !!..
-
Originally Posted by janner
To much enthusiasm noodles.. Down boy.. Down !!..
Agreed. I will wait for it to become reasonably priced on it's current earnings. Then s-clave can be a free upside option.
-
Originally Posted by Lizard
New management team in 2011 seem to be pulling things back on track. Combined with strong dairy industry demand (new production lines), potential residential building demand increase, growth from acquisitions (Titan Slicers) and launch of new products (e.g. today's announcement - previously foreshadowed - of North American licence agreement for the S-Clave technology). All starts to look like a baby version of SCT.
Okay, so 21 cps ($58m market cap) is probably more than a little overpriced... compare with SCT at $89m market cap and generating a $5m+ NPAT, whereas MGL managed just $0.8m. However, licensing revenues have the potential to drop through to bottom line rather nicely, so could provide a bit of a boost - especially should S-clave consumables start to kick in around 3-4 years away.
AGM tomorrow may give further guidance.
Reviewing the AGM presentation to see how 'baby SCT' measures up. The profit history looks terrible (p3) five years of solid losses before the modest profit this year. Perhaps this is a result of the multisector push into IP (p15)? The 'Leak Detector' has finally been completed, so at last all of those losses that plagued the company in prior years have been stemmed?
Now we go to the balance sheet, page 27 of the FY2013 Annual Report. Trade receivables roughly match trade payables -OK. My main concern is the increase in borrowings (note 20, FY2013 report) up from $4.967m (FY2012) up to $6.337m (FY2013). Now $6.337m on total assets of $31.086m represents total long and short term debt to equity apportionment on 20:80. Pretty good, but not in the league of SCT who have a policy of zero term debt.
ROE based on shareholder equity of $17.233m and $0.778m of profit ignoring currency translation differences is just 4.5%.
Poor little baby! Perhaps best to put him back in the intensive care business incubator for another year and see what happens. I think he will pull through but he needs some better numbers behind him before I would become a supporter.
SNOOPY
discl: hold SCT and it is analyses like these that make me realize what a good investment, in relative terms, it is
Watch out for the most persistent and dangerous version of Covid-19: B.S.24/7
-
WOW approx. 11% changed hands today, whose selling and WHATSUP ?
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks